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Expanded Abstract 
Citation 
Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, 
Elbourne D, Brampton W, Williams D, Young D, Rowan K: 
Assessment of the clinical effectiveness of pulmonary artery 
catheters in management of patients in intensive care (PAC-
Man): a randomized controlled trial. Lancet 2005, 366:472-
477 [1]. 
Background 
Over the past 30 years, the pulmonary artery catheter 
(PAC) has become a widely used hemodynamic monitoring 
device in the management of the critically ill. However, 
doubts have been raised regarding its benefits and safety. 
The aim of this study was, therefore, to ascertain whether 
hospital mortality is reduced in critically ill patients when 
they are managed with a PAC. 
Methods 
Design and setting: Prospective, randomized controlled 
trial of 1041 subjects enrolled in 65 British ICUs. 
Subjects and intervention: Patients identified by the 
treating physician as someone who should be managed 
using invasive hemodynamic monitoring were randomized 
to management with (n=519) or without (n=522) a PAC. 
Subsequent clinical management was at the discretion of 
the treating clinician. Patients allocated to management with 
a PAC had the catheter placed as soon as possible after 
randomization. ICUs were stratified a priori depending on 
whether they wished to have the option of using an 
alternative cardiac output-monitoring device (other than 
CVP monitoring and clinical examination) in control patients. 
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Outcomes: The primary end-point of the study was hospital 
mortality. 
Results 
After exclusion of 27 patients due to lack of consent after 
randomization, there were 1014 subjects eligible for 
analysis. No difference in hospital mortality between 
subjects managed with or without a PAC was noted (68% 
[346 of 506] vs. 66% [333 of 507], p=0.39; adjusted hazard 
ratio 1.09, 95% CI 0.94–1.27). Complications associated 
with insertion of a PAC were noted in 46 of 486 (10%) 
individuals in whom the device was placed but none were 
considered fatal. Complications were not recorded in the 
control arm, precluding conclusions regarding the relative 
safety of the PAC. Of patients randomized to receive either 
a PAC or no monitor of cardiac output, mortality was 71% 
[75 of 105] vs. 66% [71 of 107], p=0.46, respectively 
(adjusted hazard ratio 1.21, 95% CI 0.87-1.68). Of patients 
randomized in ICUs allowing the possibility of an alternative 
monitor of cardiac output, mortality was 68% [271 of 401] 
vs. 66% [262 of 400], p=0.55, respectively (adjusted hazard 
ratio 1.06, 95% CI 0.90-1.26). 
Conclusion 
The authors conclude their findings indicate no clear 
evidence of benefit or harm in managing critically ill patients 
with a PAC and suggest efficacy studies that couple PAC 
use to explicit management protocols are necessary. 
Commentary 
While knowledge of PAC-derived data has obvious appeal, 
concern emerged in the early 1990s that PAC use might be 
associated with higher mortality. An attempt to conduct a 
randomized controlled trial failed in 1991 when only thirty-
three of 148 potentially eligible patients were randomized   
[2]. Subsequently, a large retrospective study by Connors et 
al. concluded PAC use was associated with increased 30-
day mortality (odds ratio 1.24) [3]. This study was a 
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substantial improvement on prior non-randomized studies. 
Moreover, this paper’s main conclusion was that the PAC 
had been shown to be of such questionable utility that there 
is sufficient equipoise for a randomized controlled trial. A 
controversial accompanying editorial called for a moratorium 
on PAC use in the absence of such data [4]. In response, 
there have been a number of large randomized trials of the 
PAC in a variety of patient populations. The PAC was 
shown to be without benefit when the device was used to 
guide goal directed perioperative care or care for congestive 
heart failure [5,6], though most patients in the PAC arm of 
the perioperative care study failed to achieve the specified 
physiological goals in the pre- or intra-operative period [6]. 
Prior to PAC-Man, only two randomized controlled trials of 
PAC use in a general ICU population had been published. 
One of these studies was markedly underpowered [7], while 
a recent French study showed the PAC had no effect on 
mortality [8]. The power of the French study was also less 
than planned due to slower than expected enrollment, such 
that there was eventually only 78% power to detect a 10% 
absolute difference in mortality. 
The current study is the largest and best-powered trial thus 
far in a general intensive care population and has yet again 
failed to demonstrate any benefit with PAC use. The study 
had an 82% power to detect a 10% change in mortality. 
While the authors present most of their results as a 
comparison of PAC versus no PAC, this approach ignores 
the fact that essentially two studies were performed: one of 
PAC vs. no cardiac output (CO) monitor (stratum A), and 
the other of PAC vs. an alternate CO monitor (stratum B). 
Combining the studies answers the question ”do PACs 
provide any benefit over conventional practice, whatever 
that is?” but not ”are PACs superior to no monitor of CO?” 
or “are PACs superior to less invasive monitors of CO?.” 
Based on pilot studies, the authors expected half of the 
units to opt for each stratum, which (with 650 patients in 
each group) would have given a 62% power to detect a 
change in hospital mortality in each group (Harvey, personal 
communication). As it turned out, the perceived utility of CO 
monitoring by at least some means was such that 79% of 
patients were enrolled in units that had elected to join 
Stratum B. Though an analysis comparing outcome of 
patients who actually received an alternate CO monitor to 
those in the PAC group was not presented, this was 
presumably adequately powered. A post-hoc analysis is 
currently in preparation, based on the observation that 
mortality in all three groups (PAC, no PAC, and no PAC +/- 
some other CO monitor) was very similar, suggesting that 
either few patients in the no PAC +/- other CO monitor 
group actually received a CO monitor, or that no monitor of 
CO output had an impact on mortality. This post-hoc 
analysis should hopefully further delineate the utility of CO 
monitoring by any means (Harvey, personal 
communication). 
PAC-Man was an effectiveness, or pragmatic, study of the 
PAC in actual practice, and so did not rely on treatment 
directed by protocol. Because the PAC is already 
disseminated, such a study is warranted. However, it is 
possible that the lack of benefit was because clinicians did 
not act on PAC data ”correctly.” Of note, however, there 
was no outcome difference in ICUs with differing prior PAC 
experience. Another trial which has just completed 
enrollment but is not yet analyzed, the NIH-funded Fluid and 
Catheter Treatment Trial (FACTT), represents an attempt to 
conduct an efficacy trial where the interpretation and 
subsequent decisions were entrained within tightly 
administered protocols. This study has generated 
considerable controversy even before its completion, 
because of disagreement over what constitutes a safe 
approach to fluid management in the critically ill [9]. If 
FACTT is positive, it will provide clear direction regarding 
PAC use and the best associated management decisions. 
However, a negative trial may simply stir on-going debate 
about what constitutes the “correct” use and interpretation of 
PAC-derived data. 
One interesting observation from PAC-Man was the 
decision by the majority of ICUs to participate in stratum B. 
In other words, clinicians in most of the ICUs felt that some 
attempt to monitor central hemodynamics was required, 
even though the alternative monitoring devices employed 
have undergone even less scrutiny in large randomized 
trials than the PAC. The wide dissemination of the PAC 
before rigorous evaluation has made subsequent 
assessment of its value very difficult, with lack of equipoise 
hampering randomization and numerous opinions regarding 
how the PAC should be used complicating study design. 
Determining the worth of new monitoring devices may prove 
equally difficult given the ongoing desire to adopt them 
before adequate evaluation has been completed. 
There have now been at least six randomized controlled 
trials of PAC use in general or specialist intensive care, 
none of which has shown the PAC to be of harm or benefit. 
Nonetheless, PAC use continues, with no standardized 
agreement about what represents appropriate use. As with 
the thermometer, which assigns a number to a clinical 
condition relatively easily assessed by clinical examination, 
the benefit may be to the physician (in terms of ease of 
management) rather than the patient (in terms of outcome). 
While an effect on mortality has not been seen in these PAC 
trials, complications have been reported. For example, there 
was a higher rate of pulmonary embolism in a prior 
Canadian study [6]. Furthermore, all central lines are 
associated with a variety of complications related to 
placement and infection, some of which are life-threatening, 
even if rare. 
Recommendation 
Given the difficulty demonstrating patient benefit, we 
recommend that the clinician weigh carefully the perceived 
benefits, which may be largely intangible, against the small, 
but non-zero, risk of harm to the patient. Until an alternative 
is found superior, the decision to insert a PAC must be 
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made on a case-by-case basis. Use of the PAC should be 
much more selective than in the past, and in many 
instances should perhaps also involve discussion with the 
patient or family. In the meantime, the safety and efficacy of 
alternative monitors of cardiac output must be tested, if the 
mistakes associated with the widespread adoption of the 
PAC are to be avoided. 
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